BioSpace News Archive

The Decentralized Trials & Research Alliance (DTRA) today announced priorities and initial initiatives designed to realize the full potential of decentralized research to improve access and participation to make clinical trials more efficient, accessible, and equitable.

InnerScope Hearing Technologies Inc., an emerging and disruptive leader in the Direct-to-Consumer Hearing Technology space, is pleased to announce that it has retained the services of Skyline Corporate Communications Group, LLC to assist with the management of its investor relations and corporate communications activities within the financial community.

Kedrion to acquire, for a total of USD 17M , 2 plasma collection centers and an option to acquire the remaining plasma-derived therapeutic business for USD 5M Liminal to receive up to 70% of net proceeds from sale of Priority Review Voucher for which it is potentially eligible with possible FDA approval for Ryplazim ®

EpiVax, Inc. (“EpiVax”) announces the publication “Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation” in NPJ Vaccines .

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Kumar Srinivasan, Ph.D., MBA, as executive vice president and chief business officer, effective June 1

Abbott (NYSE: ABT) today announced it has received CE Mark for its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor™, making the minimally invasive device available for people in Europe with severe aortic stenosis who are at high or extreme surgical risk

Defender Safety, a trusted construction and healthcare safety products producer, recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ASTM Level 1 Procedure Mask, ASTM Level 3 Procedure Mask, and ASTM Level 3 Surgical Mask.

ENDRA Life Sciences Inc., a pioneer of Thermo Acoustic Enhanced UltraSound, reported financial results for the three months ended March 31, 2021 and provided a business update.

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (“SEC”), under which it may offer and sell, from time to time, shares of its common stock having an aggregate offering price of up to $75,000,000 million through an “at-the-market” equity offering program (the “ATM Program”).

The Board of Directors of SWK Holdings Corporation and its controlling stockholder, funds affiliated with Carlson Capital, L.P., announced that the Board and Carlson have jointly agreed that the Board will form a strategic review committee to identify, review and explore strategic alternatives for the Company with a view to maximizing stockholder value.